Go Pro
→ Trump Takes Emergency Action - Plus Elon Musk's New Venture (From Altimetry) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
$5.36
-4.1%		$4.78
$2.78
▼
$6.45
$448.34M0.3383,673 shs214,280 shs
CCXI
Churchill Capital Corp XI
$14.07
-3.6%		$14.60
$10.07
▼
$19.69
$1.00B1.221.52 million shs2.15 million shs
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$12.56
-0.2%		$11.27
$9.77
▼
$18.30
$2.20B0.2355,343 shs49,946 shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
-4.11%+5.72%+10.06%+21.27%+53.14%
CCXI
Churchill Capital Corp XI
-3.63%-13.09%-5.12%+36.87%+1,406,999,900.00%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
-0.24%+3.29%+12.34%+4.75%-20.91%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
$5.36
-4.1%		$4.78
$2.78
▼
$6.45
$448.34M0.3383,673 shs214,280 shs
CCXI
Churchill Capital Corp XI
$14.07
-3.6%		$14.60
$10.07
▼
$19.69
$1.00B1.221.52 million shs2.15 million shs
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$12.56
-0.2%		$11.27
$9.77
▼
$18.30
$2.20B0.2355,343 shs49,946 shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
-4.11%+5.72%+10.06%+21.27%+53.14%
CCXI
Churchill Capital Corp XI
-3.63%-13.09%-5.12%+36.87%+1,406,999,900.00%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
-0.24%+3.29%+12.34%+4.75%-20.91%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
2.33
Hold$7.0030.60% Upside
CCXI
Churchill Capital Corp XI
1.00
SellN/AN/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
2.17
Hold$14.8718.37% Upside

Current Analyst Ratings Breakdown

Latest CCXI, AVIR, and HCM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/18/2026
CCXI
Churchill Capital Corp XI
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E) ➝ Sell (D)
8/13/2026
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$6.00 ➝ $7.00
8/3/2026
CCXI
Churchill Capital Corp XI
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E)
7/31/2026
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold (C-) ➝ Sell (D)
7/23/2026
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetNeutral$16.00 ➝ $14.00
7/17/2026
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/17/2026
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D+) ➝ Hold (C-)
7/7/2026
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
Bank of America Corporation logo
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$20.00 ➝ $17.00
6/29/2026
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold (C-) ➝ Sell (D+)
5/28/2026
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$13.60
(Data available from 8/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
N/AN/AN/AN/A$2.55 per shareN/A
CCXI
Churchill Capital Corp XI
$37.20M26.99N/AN/AN/A∞
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$548.51M4.00$2.69 per share4.67$7.31 per share1.72
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
-$158.35M-$2.08N/AN/AN/AN/A-64.25%-57.12%N/A
CCXI
Churchill Capital Corp XI
N/A-$1.89N/AN/AN/AN/AN/AN/AN/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$456.91MN/AN/A57.09N/AN/AN/AN/AN/A

Latest CCXI, AVIR, and HCM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2026Q2 2026
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
-$0.5550-$0.41+$0.1450-$0.41$33.03 millionN/A
7/30/2026H1 2026
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$0.1450$0.05-$0.0950$0.05$304.16 million$139.14 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
N/AN/AN/AN/AN/A
CCXI
Churchill Capital Corp XI
N/AN/AN/AN/AN/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
N/A
8.13
8.13
CCXI
Churchill Capital Corp XI
N/AN/AN/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
0.06
5.64
5.50

Institutional Ownership

CompanyInstitutional Ownership
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
86.67%
CCXI
Churchill Capital Corp XI
81.09%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
8.82%

Insider Ownership

CompanyInsider Ownership
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
21.60%
CCXI
Churchill Capital Corp XI
8.30%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
3.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
7080.21 million62.88 millionOptionable
CCXI
Churchill Capital Corp XI
N/A71.36 millionN/AN/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
1,796174.47 million168.19 millionNot Optionable

Recent News About These Companies

HUTCHMED (NASDAQ:HCM) Shares Gap Down - Here's Why
August 19 at 12:59 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hutchmed-nasdaqhcm-shares-gap-down-heres-why-2026-08-19/
AZN Ends NSCLC Study for Bispecific Antibody Over Unlikely Success
August 18 at 1:01 PM  |  zacks.comhttps://www.zacks.com/stock/news/2976446/azn-ends-nsclc-study-for-bispecific-antibody-over-unlikely-success?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-2976446
HUTCHMED (NASDAQ:HCM) Sees Strong Trading Volume - Should You Buy?
August 18 at 11:59 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hutchmed-nasdaqhcm-sees-strong-trading-volume-should-you-buy-2026-08-18/
HUTCHMED shares rise as lung cancer drug trial hits key targets
August 17, 2026  |  proactiveinvestors.co.ukhttps://www.proactiveinvestors.co.uk/companies/news/1097128?snapi
HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET ...
August 17, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/hutchmed-announces-orpathys-plus-tagrisso-demonstrated-statistically-significant-and-clinically-meaningful-improvements-in-progression-free-and-overall-survival-in-met-driven-egfr-mutated-lung-1036462412
HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO®
August 16, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/17/3345800/0/en/hutchmed-announces-orpathys-plus-tagrisso-demonstrated-statistically-significant-and-clinically-meaningful-improvements-in-progression-free-and-overall-survival-in-met-driven-egfr-.html
HUTCHMED (NASDAQ:HCM) Stock Rating Upgraded by Wall Street Zen
August 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hutchmed-nasdaqhcm-stock-rating-upgraded-by-wall-street-zen-2026-08-08/
HUTCHMED (NASDAQ:HCM) Share Price Crosses Above 50 Day Moving Average - Here's Why
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hutchmed-nasdaqhcm-share-price-crosses-above-50-day-moving-average-heres-why-2026-08-07/
HUTCHMED (NASDAQ:HCM) Announces Earnings Results
July 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hutchmed-nasdaqhcm-announces-earnings-results-2026-07-30/
HUTCHMED Reports 2026 Interim Results
July 31, 2026  |  tmcnet.comhttps://www.tmcnet.com/usubmit/2026/07/30/10422590.htm
HUTCHMED (China) Limited (HCM) Q2 2026 Earnings Call Transcript
July 30, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4928139-hutchmed-china-limited-hcm-q2-2026-earnings-call-transcript
HUTCHMED H1 Earnings Call Highlights
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hutchmed-h1-earnings-call-highlights-2026-07-30/
HUTCHMED (China) Limited 2026 Q2 - Results - Earnings Call Presentation
July 30, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4927756-hutchmed-china-limited-2026-q2-results-earnings-call-presentation
Hutchmed China Ltd. Reveals Fall In H1 Income
July 30, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-07/69170470-hutchmed-china-ltd-reveals-fall-in-h1-income-020.htm
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Average Rating of "Hold" from Brokerages
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hutchmed-china-limited-sponsored-adr-nasdaqhcm-receives-average-rating-of-hold-from-brokerages-2026-07-30/
HUTCHMED (HCM) Projected to Release Earnings on Thursday
July 23, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hutchmed-hcm-projected-to-release-earnings-on-thursday-2026-07-23/
Hutchmed: Bullish On Their Commercial Prospects And Pipeline Catalysts
July 19, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4923287-hutchmed-stock-bullish-commercial-prospects-pipeline-catalysts
HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification
July 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/02/3321131/0/en/hutchmed-announces-nmpa-approval-for-orpathys-for-the-treatment-of-gastric-cancer-patients-with-met-amplification.html
HUTCHMED to Announce 2026 Half-Year Financial Results
June 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/30/3319446/0/en/hutchmed-to-announce-2026-half-year-financial-results.html
HUTCHMED's experimental drug shows durable responses in advanced bile duct cancer trial
June 25, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/hutchmeds-experimental-drug-shows-durable-responses-in-advanced-bile-duct-cancer-trial/ar-AA26xHm7
Syndio Acquires Embrace.ai
June 23, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260623406678/en/syndio-acquires-embrace.ai/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Atea Pharmaceuticals stock logo

Atea Pharmaceuticals NASDAQ:AVIR

$5.36 -0.23 (-4.11%)
Closing price 08/20/2026 04:00 PM Eastern
Extended Trading
$5.22 -0.14 (-2.61%)
As of 08/20/2026 06:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Churchill Capital Corp XI NASDAQ:CCXI

$14.07 -0.53 (-3.63%)
Closing price 08/20/2026 04:00 PM Eastern
Extended Trading
$14.50 +0.43 (+3.04%)
As of 04:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Churchill Capital Corp XI is a blank check company.

HUTCHMED stock logo

HUTCHMED NASDAQ:HCM

$12.56 -0.03 (-0.24%)
As of 08/20/2026 04:00 PM Eastern

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas